| Allergic rhinitis (disorder)
Dymista vs Rayos
Side-by-side clinical, coverage, and cost comparison for allergic rhinitis (disorder).Deep comparison between: Dymista vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Dymista based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Dymista, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dymista
Rayos
At A Glance
Nasal spray
Twice daily
H1 antagonist/corticosteroid combination
Oral
Daily
Corticosteroid
Indications
- Allergic rhinitis (disorder)
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Allergic rhinitis (disorder) 1 spray (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate) per nostril twice daily, by nasal route only.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Hypersensitivity to azelastine hydrochloride, fluticasone propionate, or any other ingredient of DYMISTA (including anaphylaxis)
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=2%) Dysgeusia, headache, epistaxis
Serious Somnolence, epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, Candida albicans infection, glaucoma, cataracts, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Atrial fibrillation, palpitations, increased heart rate, blurred vision, cataracts, glaucoma, increased intraocular pressure, nausea, vomiting, anaphylaxis, growth suppression, disturbance or loss of smell and/or taste, dizziness, urinary retention, bronchospasm, dyspnea, nasal septal perforation, angioedema, hypertension
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
DYMISTA combines azelastine hydrochloride, a histamine H1-receptor antagonist (phthalazinone derivative), and fluticasone propionate, a synthetic trifluorinated corticosteroid that exerts anti-inflammatory activity on multiple cell types (mast cells, eosinophils, macrophages, lymphocytes) and mediators (histamine, leukotrienes, cytokines) involved in allergic rhinitis.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dymista
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Dymista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Dymista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Dymista.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DymistaView full Dymista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.